173 related articles for article (PubMed ID: 31189814)
1. [Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab].
Ueki D; Yoshida C; Tsutsumi Oota I; Seki M; Komeno T; Ito H; Ide Y
Gan To Kagaku Ryoho; 2019 May; 46(5):913-915. PubMed ID: 31189814
[TBL] [Abstract][Full Text] [Related]
2. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
Vivekanandarajah A; Atallah JP; Gupta S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
[TBL] [Abstract][Full Text] [Related]
3. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
4. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
[TBL] [Abstract][Full Text] [Related]
5. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
6. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract][Full Text] [Related]
7. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
8. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.
Dearden CE; Khot A; Else M; Hamblin M; Grand E; Roy A; Hewamana S; Matutes E; Catovsky D
Blood; 2011 Nov; 118(22):5799-802. PubMed ID: 21948296
[TBL] [Abstract][Full Text] [Related]
10. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
11. Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.
Meeuse JJ; Sprenger HG; van Assen S; Leduc D; Daenen SM; Arends JP; van der Werf TS
Emerg Infect Dis; 2007 Dec; 13(12):1942-3. PubMed ID: 18258054
[TBL] [Abstract][Full Text] [Related]
12. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
[TBL] [Abstract][Full Text] [Related]
14. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract][Full Text] [Related]
15. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Pflug N; Cramer P; Robrecht S; Bahlo J; Westermann A; Fink AM; Schrader A; Mayer P; Oberbeck S; Seiler T; Zenz T; Dürig J; Kreuzer KA; Stilgenbauer S; Eichhorst B; Hallek M; Herling M; Hopfinger G
Leuk Lymphoma; 2019 Mar; 60(3):649-657. PubMed ID: 30234404
[TBL] [Abstract][Full Text] [Related]
16. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
[TBL] [Abstract][Full Text] [Related]
18. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Hopfinger G; Busch R; Pflug N; Weit N; Westermann A; Fink AM; Cramer P; Reinart N; Winkler D; Fingerle-Rowson G; Stilgenbauer S; Döhner H; Kandler G; Eichhorst B; Hallek M; Herling M
Cancer; 2013 Jun; 119(12):2258-67. PubMed ID: 23512246
[TBL] [Abstract][Full Text] [Related]
19. Coronary vasculitis associated with T-cell prolymphocytic leukemia.
Audemard A; Boutemy J; Guilpain P; Sabatier R; Silva NM; Bienvenu B
Joint Bone Spine; 2014 Jan; 81(1):93-4. PubMed ID: 23731632
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia.
Lu L; Peters J; Roome C; Stein K
Int J Technol Assess Health Care; 2012 Jul; 28(3):241-8. PubMed ID: 22980700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
